149 results on '"Noureddin, Mazen"'
Search Results
2. Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women: Global Trends and Projections to 2040
3. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
4. The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults
5. Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort
6. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020
7. Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly
8. The Global Burden of Early-Onset Biliary Tract Cancer: Insight From the Global Burden of Disease Study 2019
9. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
10. Defining Small Intestinal Bacterial Overgrowth by Culture and High Throughput Sequencing
11. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
12. Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma
13. Implementation of a liver health check in people with type 2 diabetes
14. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States
15. A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
16. NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
17. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
18. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
19. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
20. MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death
21. The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals
22. A global research priority agenda to advance public health responses to fatty liver disease
23. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
24. A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials
25. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
26. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment
27. Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD – An Umbrella Overview of Systematic Review of Meta-Analysis
28. Caring for the Liver: Updates on Global Prevalence, Cutting-Edge Diagnosis, and State-of-the-Art Management for Researchers and Clinicians, 2023 and Beyond
29. Clinical Trial Landscape in NASH
30. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
31. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies
32. Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology
33. The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–2019
34. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease–Associated Hepatocellular Carcinoma in the United States
35. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD
36. Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency
37. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
38. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
39. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review
40. The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis
41. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
42. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
43. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
44. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
45. The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease
46. The impact of COVID-19 on the cascade of care of HCV in the US and China
47. Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population
48. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
49. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
50. Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.